Telik Telcyta vs. Iressa
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Telik initiates a Phase III registration trial comparing its apoptosis-inducing oncologic Telcyta to AstraZeneca's Iressa for single-agent, third-line treatment of non-small cell lung cancer. ASSIST-2 (Assessment of Survival In Solid Tumors-2) will randomize 520 patients to either Telcyta (TLK286) or Iressa (gefitinib); endpoints include survival, time to tumor progression and objective response rate. Another registration trial, in women with resistant ovarian cancer (ASSIST-1), is underway. Other ongoing studies include combination regimens in NSCLC and ovarian cancer, and a single-agent study in previously untreated metastatic breast cancer. ASSIST-1 and -2 are both under special protocol assessments with FDA, Telik notes. Telcyta has fast-track designation for both indications...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.